drugset
drugset / Trial / NCT04395053

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

NCT04395053 ↗

Phase 1 Completed 28 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelBasic science

Summary

The primary objective of the study is to evaluate the pharmacokinetics of healthy Chinese volunteers after oral administration of SHR1459 tablets in new and old formulations. The secondary objective of the study is to evaluate the safety after single dose of SHR1459 orally in healthy Chinese subjects.

Timeline

Start
2020-06-28
Primary completion
2020-07-11
Completion
2020-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject EDRALBRUTINIB Small molecule — Oral

Indications

No indication recorded.